US 11,666,632 B2
Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
Carsten Brockmeyer, Marzling (DE); Christopher Weikart, Auburn, AL (US); Murray Stephen Bennett, Bellingham, WA (US); Jean-Pierre Giraud, Auburn, AL (US); and Thomas Strungmann, Munich (DE)
Assigned to FORMYCON AG, Planegg (DE); SIO2 MEDICAL PRODUCTS, INC., Auburn, AL (US); and KLINGE BIOPHARMA GMBH, Holzkirchen (DE)
Filed by FORMYCON AG, Martinsried/Planegg (DE); SIO2 MEDICAL PRODUCTS, INC., Auburn, AL (US); and KLINGE BIOPHARMA GMBH, Holzkirchen (DE)
Filed on Feb. 26, 2022, as Appl. No. 17/681,730.
Application 17/681,730 is a continuation of application No. 17/154,702, filed on Jan. 21, 2021, granted, now 11,298,405.
Application 17/154,702 is a continuation of application No. 15/777,276, granted, now 10,925,927, previously published as PCT/US2016/062767, filed on Nov. 18, 2016.
Claims priority of provisional application 62/257,210, filed on Nov. 18, 2015.
Prior Publication US 2022/0175883 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 9/00 (2006.01); C07K 16/22 (2006.01); A61M 5/31 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/179 (2013.01) [A61K 9/0019 (2013.01); A61K 39/39591 (2013.01); A61M 5/3129 (2013.01); C07K 16/22 (2013.01); A61K 45/06 (2013.01); A61K 2300/00 (2013.01); A61M 2005/3131 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, wherein the pre-filled pharmaceutical package comprises:
a wall comprising a cyclic olefin polymer, having an interior surface enclosing at least a portion of a lumen;
a tie coating or layer on the wall interior surface comprising SiOxCyHz, in which x is from about 0.5 to about 2.4 as measured by X-ray photoelectron spectroscopy (XPS), y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of Rutherford backscattering spectrometry (RBS) or hydrogen forward scattering (HFS);
a barrier coating or layer of SiOx, in which x is from about 1.5 to about 2.9 as measured by XPS, the barrier coating or layer positioned between the tie coating or layer and the lumen;
a pH protective coating or layer of SiOxCyHz, in which x is from about 0.5 to about 2.4 as measured by XPS, y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of RBS or HFS, positioned between the barrier coating or layer and the lumen;
a lubricity coating or layer positioned between the pH protective coating or layer and the lumen, wherein the lubricity coating or layer has the atomic proportions SiOxCyHz, in which x is from about 0.5 to about 2.4 as measured by XPS, y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of RBS or HFS;
a liquid formulation of a VEGF-antagonist in the lumen; and
a closure closing the lumen;
wherein the VEGF antagonist is Aflibercept.